Overview

Study of OT-101 in Treating Myopia

Status:
Recruiting

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects

Phase:

Phase 3

Details

Lead Sponsor:

Ocumension (Hong Kong) Limited

Collaborators:

ORA, Inc.
Statistics & Data Corporation

Treatments:

Ophthalmic Solutions